Filing summary
Entity and period: The supplied filing is Aziyo Biologics, Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 8, 2022. This does not match the request metadata naming ELUTIA INC.; verify that this is the intended filing. The filing reports annual results, not a separate fourth-quarter income statement.
Business context
Aziyo is a commercial-stage regenerative medicine company selling tissue-based products for implantable electronic devices and cardiovascular procedures, orthopedic and spinal repair, and soft-tissue reconstruction. It also processes tissue products under contract manufacturing arrangements. Sales are primarily in the United States and depend substantially on commercial partners and independent sales agents.
Financial results and liquidity
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Net sales | $47.4 million | $42.7 million |
| Core Products sales | $37.6 million | $36.2 million |
| Non-Core Products sales | $9.8 million | $6.5 million |
| Gross profit / gross margin | $19.0 million / 40.1% | $20.6 million / 48.2% |
| Gross margin excluding intangible amortization (non-GAAP) | 47.3% | 56.1% |
| Operating expenses | $42.1 million | $34.2 million |
| Loss from operations | $23.0 million | $13.6 million |
| Net loss | $24.8 million | $21.8 million |
| Net cash used in operating activities | $15.4 million | $13.6 million |
At December 31, 2021, cash was $30.4 million and restricted cash was $0.04 million. Current assets were $47.4 million and current liabilities were $26.0 million. Total assets were $67.2 million, total liabilities $53.6 million, and stockholders’ equity $13.5 million. The accumulated deficit was $105.1 million.
Reported debt was approximately $23.3 million, including $17.1 million under the term loan, $4.8 million under the revolving facility, and a $1.4 million supplier note. The revolving facility had $2.1 million of additional availability. Separately, the Ligand revenue-interest obligation requires 5% of specified product sales, subject to $2.75 million annual minimum payments and potential $5 million sales milestones. Term-loan principal payments began in August 2021; the remaining balance is due in July 2024.
Changes versus prior year
- Net sales increased 11.0%; Core Products sales rose 3.8%, while Non-Core Products sales rose 51.4% and grew to 20.7% of sales.
- Gross margin fell 8.1 percentage points. Management attributed the decline mainly to greater lower-margin contract manufacturing sales, lower orthopedic/spinal product yields, and inventory write-downs; the latter two together reduced 2021 gross margin by approximately 4 percentage points.
- Operating expenses increased 23.1%, with higher general and administrative costs, including public-company costs, and higher research and development spending, particularly on an antibiotic version of CanGaroo.
- Operating cash use increased by $1.8 million. Financing cash inflow fell substantially from 2020, when the company completed its IPO; 2021 included a December private placement with net proceeds of approximately $13.8 million.
Outlook, risks and unusual items
- Liquidity outlook: Management expected cash, revolver availability, anticipated commercial receipts, and prior financing proceeds to fund operating costs, debt service, and capital needs for at least twelve months from issuance of the financial statements. This is an estimate based on assumptions; management also said it may need further capital, refinancing, restructuring, or asset sales. The auditor highlighted continuing losses and potential liquidity impact.
- FiberCel recall and litigation: A June 2021 voluntary recall covered one donor lot after infections, including tuberculosis, were reported. The lot comprised 154 units; 136 were implanted in 113 patients, and the CDC reported at least 75 patients with findings consistent with tuberculosis infection. Eight recipients had died, with causes of death still under investigation in the filing. The company reported 45 lawsuits and 42 additional claims; it could not estimate a probable loss range and warned the exposure could materially affect financial position and results. Insurance coverage is disputed or may be limited.
- Medtronic distribution: Medtronic suspended purchases of FiberCel and other supplied Non-Core products in June 2021, later ended distribution of cellular bone products, and mutually terminated the FiberCel agreement in December. The related lender default was waived, but reduced sales may affect future revenue-covenant compliance.
- Other unusual income: 2021 other income included approximately $3.0 million of PPP loan forgiveness and $0.55 million received in settlement with KeraLink. In 2020, other expense included a $2.3 million loss on early debt extinguishment; preferred-stock accretion also affected 2020 loss attributable to common stockholders.
- Development: The company completed design and manufacturing validation for CanGaroo with antibiotics and anticipated submitting a 510(k) by the end of Q1 2022. This was a forward-looking expectation, not confirmation of submission or clearance.
- Operating risks: COVID-19 continued to disrupt procedure volumes, facility access, manufacturing, and clinical activity. Other material risks include persistent losses, dependence on partners and contract customers, sole-source porcine tissue supply, reimbursement and competitive pressures, variable-rate debt, and potential covenant constraints.
- Seasonality: Management described typically higher fourth-quarter sales and lower first-quarter sales, partly reflecting hospital budget cycles and patient deductibles.
- Controls: Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2021; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the filing identity: the supplied 10-K is for Aziyo Biologics, Inc., not ELUTIA INC.
- Review the latest FiberCel litigation, investigation, insurance-coverage, and potential-loss disclosures; the filing provides no estimable loss range.
- Track Medtronic’s lost distribution, bone-product sales recovery, and the effect on revenue covenants and customer concentration.
- Assess whether gross margins and cash burn improve as product mix, yields, inventory adjustments, and commercial activity change.
- Check subsequent liquidity, financing, debt amendments, covenant compliance, and Ligand payments against management’s stated twelve-month runway expectation.
- Verify the status and regulatory pathway of CanGaroo with antibiotics, and whether SimpliDerm obtains adequate reimbursement and any required regulatory authorization for targeted indications.